市場調查報告書
商品編碼
927799

心律不整治療藥的市場:成長,趨勢,預測(2020年∼2025年)

Cardiac Arrhythmia Therapeutics Market - Growth, Trends And Forecast (2020 - 2025)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 105 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

心律不整治療藥市場在預測期間內預計將為4.3%的年複合成長率。心律不整,定義是不規則或異常的心率。心律不整有心搏過緩和心搏過速2種。每分鐘不滿60下的緩慢心率是心搏過緩,每分鐘不滿100下以上的快速心率是心搏過速。心律不整的症狀案例,是心率快或慢、發汗、呼吸急促、胸的疼痛、少跳、暈眩。冠狀動脈疾病,高血壓,肥胖和過重,酒精的過量攝取,壓力,高膽固醇,抽煙,是提高心律不整發病可能性的要素。

本報告提供心律不整治療藥市場調查,市場概要,各市場成長要素及阻礙因素分析,各藥物類別、各地區的市場規模的變化與預測,競爭情形,主要企業的簡介,市場機會等全面性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 老年人口的增加和慢性疾病的發生率
    • 研究開發的投資增加
  • 市場抑制
    • 嚴格法規標準
  • 波特的五力分析

第5章 市場細分化

  • 各藥物類別
    • 鈉流通管道阻斷劑
    • β- 阻斷劑
    • 鉀流通管道阻斷劑
    • 鈣離子通道阻斷劑
    • 其他藥物類別
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd
    • Pfizer Inc
    • Sanofi
    • Upsher-Smith Laboratories, LLC
    • Covis Pharma
    • Novartis AG
    • Mayne Pharma Group Limited
    • Eli Lilly and Company

第7章 市場機會及未來趨勢

目錄
Product Code: 68291

The Cardiac Arrhythmia Therapeutics Market is expected to register a CAGR of 4.3% during the forecast period. Arrhythmia is defined as irregular or abnormal heartbeat. Arrhythmia is of two types bradycardia and tachycardia. When the heartbeat is too slow, less than 60 beats per minute, it is known as bradycardia and when it is too fast, more than 100 beats per minute, it is known as tachycardia. Some of the symptoms of arrhythmia are fast or slow heartbeat, sweating, shortness of breath, chest pain, skipping beats and dizziness. Coronary artery disease, high blood pressure, obesity/overweight, excessive use of alcohol, stress, high cholesterol, smoking are the factors which can increase the chance of developing arrhythmia.

The most common type of arrhythmia is atrial fibrillation, which causes an irregular and fast heartbeat. As per the study published in the Journal of Geriatric Cardiology, atrial fibrillation affects millions of people worldwide and left untreated which increases the risk and severity of heart failure, stroke, and death. Furthermore, atrial fibrillation (AF) is predicted to affect 17.9 million in Europe by the year 2060.

Increasing incidences of obesity, chronic diseases, rising consumption of alcohol and cigarettes, high stress, and unhealthy lifestyles, coupled with the growing awareness regarding early diagnosis of cardiovascular diseases are the key driving factors in cardiac arrhythmia therapeutics market.

Key Market Trends

Sodium-channel Blockers Segment is Expected to Hold a Major Market Share in the Cardiac Arrhythmia Therapeutics Market

  • Sodium channel blockers are class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of Sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability and conduction velocity. These blockers are used for the treatment of atrial fibrillation, ventricular tachycardia, supraventricular tachycardia, symptomatic ventricular premature beats, and prevention of ventricular fibrillation.
  • According to the Centers for Disease Control and Prevention (CDC), estimates approximately 2 percent of people younger than 65 years old have atrial fibrillation, while about 9 percent of people ages 65 and older have it. Moreover, in the United States, prevalence rate of atrial fibrillation is estimated to rise to 12.1 million by the year 2030.
  • Sodium-channel blockers segment holds a significant market share in the cardiac arrhythmia therapeutics market and is anticipated to show similar trend over the forecast period due to easy to consume, no pain, low cost and extended-release effect of drugs.
  • Increasing incidences of chronic diseases worldwide, technological advancements and growing awareness regarding early diagnosis of diseases are the key driving factors in the sodium-channel blockers segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global cardiac arrhythmia therapeutics market due to increasing geriatric population, high drug consumption & costs, and growing incidence of cardiac diseases. Centers for Disease Control and Prevention, estimates approximately 2.7 million and 6.1 million people in the United States have atrial fibrillation. In addition, in the year 2017, atrial fibrillation was responsible for 26,077 deaths in the United States. Furthermore, presence of top pharma and biotech companies, increasing healthcare spending and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Cardiac Arrhythmia Therapeutics Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Mylan N.V., Teva Pharmaceutical Industries Ltd, Pfizer Inc, Sanofi S.A, Upsher-Smith Laboratories, LLC, Covis Pharma, Novartis AG, Mayne Pharma Group Limited and Eli Lilly and Company.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Geriatric Population and Incidence of Chronic Diseases
    • 4.2.2 Increasing Investment in Research and Development
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Norms
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Sodium-channel Blockers
    • 5.1.2 Beta-blockers
    • 5.1.3 Potassium-channel Blockers
    • 5.1.4 Calcium-channel Blockers
    • 5.1.5 Other Drug Class
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Mylan N.V.
    • 6.1.2 Teva Pharmaceutical Industries Ltd
    • 6.1.3 Pfizer Inc
    • 6.1.4 Sanofi
    • 6.1.5 Upsher-Smith Laboratories, LLC
    • 6.1.6 Covis Pharma
    • 6.1.7 Novartis AG
    • 6.1.8 Mayne Pharma Group Limited
    • 6.1.9 Eli Lilly and Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS